The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2025 | Optimizing the balance between efficacy & safety when administering T-DXd in gastric cancer
Hisato Kawakami, MD, PhD, Tohoku University, Sendai, Japan, discusses balancing efficacy and safety with the use of trastuzumab deruxtecan in patients with HER2+ gastric cancer, highlighting its high response rate and prolonged patient survival, but also emphasizing the need for caution in patients with a history of lung disease. This interview took place at the ASCO GI Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
